The purpose of this contract is to acquire genome characterization center (GCC) services consisting of large-scale, high- resolution, and comprehensive sequencing and array platforms. The sequencing…
Active Awarded Last action
- Contract number
- 75N91025D00007
- Awardee
-
Seqmatic, LLC UEI T8LRGLKLMMT3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- NCI Genomic Characterization Centers Pre-Solicitation · 75N91024R00001 · Posted Dec 6, 2022
- Last date to order 35% complete
- IDV ceiling
- $149,173,285.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541380 Testing Laboratories and Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 11 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Cancer Institute awarded a multiple-award indefinite-delivery contract to Seqmatic, LLC on January 13, 2025, with a $149.17 million ceiling and an ultimate completion date of January 12, 2030. Seqmatic is a minority-owned, Asian-Pacific American-owned small business.
The IDIQ acquires Genome Characterization Center services consisting of large-scale, high-resolution, and comprehensive sequencing and array platforms, including whole exome sequencing, whole-genome sequencing, epigenetic characterization, and single-cell/single-nuclei sequencing to support NCI cancer genomics research. Performance is based in Fremont, California, with capacity maintained in St. Paul, Minnesota; Auburn, Alabama; and Silver Spring, Maryland, depending on customer location requirements.
The originating solicitation was posted as a pre-solicitation on December 6, 2022, with a due date of January 4, 2023. This is one of multiple awards under the NCI Genomic Characterization Centers program. The contract reflects compliance with Executive Order 14398 addressing DEI discrimination by federal contractors.
Seqmatic operates across NAICS 541380 (Testing Laboratories and Services) and 541714 (Research and Development in Biotechnology). The company performs all work as prime with no subcontract exposure. The contract period runs from the award date through January 12, 2030.
Description
The purpose of this contract is to acquire genome characterization center (GCC) services consisting of large-scale, high- resolution, and comprehensive sequencing and array platforms. The sequencing and array platforms include whole exome sequencing.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91025D00007?
75N91025D00007 was awarded to Seqmatic, LLC by National Cancer Institute (National Institutes of Health) on January 13, 2025.
How much is contract 75N91025D00007 worth?
75N91025D00007's own ceiling is $149,173,285.
Who can order from contract 75N91025D00007?
75N91025D00007 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N91025D00007 part of a contract vehicle?
Yes. 75N91025D00007 is part of NCI Genomic Characterization Centers.
Was contract 75N91025D00007 competed?
The extent of competition for 75N91025D00007 was full and open competition. The government received 11 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV